Skip to main content

Table 1 Association between plasma miR-655 levels and clinicopathological characteristics in ESCC patients

From: Low levels of tumour suppressor miR-655 in plasma contribute to lymphatic progression and poor outcomes in oesophageal squamous cell carcinoma

  Plasma miR-655 concentration  
Variables High (n = 61) Low (n = 61) P-valuea
Gender Female 14 (61%) 9 (39%) 0.354
Male 47 (47%) 52 (53%)
Age (60 years old) <  60 17 (74%) 6 (26%) 0.019
60 < 44 (44%) 55 (56%)
T factor T1,2 31 (50%) 31 (50%) 1.000
T3,4 30 (50%) 30 (50%)
N factor N0,1 50 (56%) 39 (44%) 0.025
N2,3,4 11 (33%) 22 (67%)
Lymphatic invasion ly0,1 56 (63%) 33 (37%) 0.004
ly2,3 5 (15%) 28 (85%)
Venous invasion v0,1 48 (51%) 46 (49%) 0.243
v2,3 8 (36%) 14 (64%)
p Stage Stage I 13 (72%) 5 (28%) 0.041
Stage II, III, IV 48 (46%) 56 (54%)
Tumor size <  50 mm 36 (54%) 31 (46%) 0.466
50 mm < 25 (45%) 30 (55%)
Histology Well and moderately differentiated 44 (48%) 47 (52%) 0.677
Poorly differentiated 17 (55%) 14 (45%)
Recurrences Absent 39 (57%) 30 (43%) 0.143
Present 22 (42%) 31 (58%)
  1. a Chi-square or Fisher tests. NOTE: significant values are in bold